Dragonfly Therapeutics Closes New Funding Round

Dragonfly Therapeutics, Inc., a Cambridge, Mass.-based developer of drugs to stimulate immune responses against cancer, closed a new investment round of undisclosed amount.

Backers included Celgene Switzerland, the Duke of Bedford, Disney family members and others.

The company intends to use the funds to accelerate development of its novel Natural Killer cell-based immunotherapies.

Led by Bill Haney, co-founder and CEO, Dragonfly Therapeutics is a discovery-stage company that harnesses the innate immune system to provide cancer treatments for patients.

FinSMEs

15/05/2017